Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities

Nature Communications

Volumn 7, Issue , 2016, Pages

  Ahmed Belkacem, Abdelhakim ^a   Colliandre, Lionel ^b,c   Ahnou, Nazim ^a   Nevers, Quentin ^a   Gelin, Muriel ^b,c   Bessin, Yannick ^b,c   Brillet, Rozenn ^a   Cala, Olivier ^d   Douguet, Dominique ^b,c   Bourguet, William ^b,c   Krimm, Isabelle ^d   Pawlotsky, Jean Michel ^a,e   Guichou, Jean Francois ^b,c  

^a HENRI MONDOR HOSPITAL   (France)

^b CENTRE DE BIOCHIMIE STRUCTURALE   (France)

^c UNIV MONTPELLIER   (France)

^d UNIVERSITÉ LYON 1   (France)

^e UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALISPORIVIR; AMPRENAVIR; CYCLOPHILIN INHIBITOR; CYCLOSPORIN A; PEPTIDYLPROLYL ISOMERASE;

DISEASE TREATMENT; HEPATITIS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; LIFE CYCLE; MOLECULAR ANALYSIS; PEPTIDE; VIRAL DISEASE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CACO 2 CELL LINE; CONTROLLED STUDY; CORONAVIRIDAE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG DETERMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG STABILITY; ENZYME INHIBITION; FRAGMENTATION REACTION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IC50; IN VITRO STUDY; JURKAT CELL LINE; LIVER MICROSOME; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; VIRUS STRAIN; X RAY CRYSTALLOGRAPHY;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84988719272     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12777     Document Type: Article

References (45)

1. De Clercq, E. Antivirals: past, present and future. Biochem. Pharmacol. 85, 727-744 (2013
2. Zhu, J. D., Meng, W., Wang, X. J., & Wang, H. C. Broad-spectrum antiviral agents. Front. Microbiol. 6, 517 (2015
3. Hopkins, S., & Gallay, P. A. The role of immunophilins in viral infection. Biochim. Biophys. Acta 1850, 2103-2110 (2014
4. Qing, J., et al. Cyclophilin A associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator. PLoS Pathog. 10, e1004422 (2014
5. Nigro, P., Pompilio, G., & Capogrossi, M. C. Cyclophilin A: a key player for human disease. Cell Death Dis. 4, e888 (2013
6. Baines, C. P., et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434, 658-662 (2005
7. Elrod, J. W., & Molkentin, J. D. Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore. Circ. J. 77, 1111-1122 (2013
8. Javadov, S., & Kuznetsov, A. Mitochondrial permeability transition and cell death: the role of cyclophilin D. Front. Physiol. 4, 76 (2013
9. Rasola, A., & Bernardi, P. Mitochondrial permeability transition in Ca(2+)-dependent apoptosis and necrosis. Cell Calcium 50, 222-233 (2011
10. Davis, T.L., et al. Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases. PLoS Biol. 8, e1000439 (2010
11. Wang, P., & Heitman, J. The cyclophilins. Genome Biol. 6, 226 (2005
12. Carbajo-Lozoya, J., et al. Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including alisporivir. Virus Res. 184, 44-53 (2014
13. Madan, V., Paul, D., Lohmann, V., & Bartenschlager, R. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation. Gastroenterology 146, 1361-1372 (2014
14. Pfefferle, S., et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 7, e1002331 (2011
15. Flisiak, R., et al. The cyclophilin inhibitor Debio-025 combined with PEG-IFN alpha-2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology 49, 1460-1468 (2009
16. Pawlotsky, J. M., et al. Alisporivir plus ribavirin, interferon-free or in combination with peg-interferon, for HCV genotype 2 or 3 infection. Hepatology 62, 1013-1023 (2015
17. Akool el, S., et al. Molecular mechanisms of TGF beta receptor-Triggered signaling cascades rapidly induced by the calcineurin inhibitors cyclosporin A and FK506. J. Immunol. 181, 2831-2845 (2008
18. Esser-Nobis, K., et al. The cyclophilin-inhibitor alisporivir stimulates antigen presentation thereby promoting antigen-specific CD8-T-cell activation. J. Hepatol. 64, 1305-1314 (2016
19. Matsuda, S., et al. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation. EMBO Rep. 1, 428-434 (2000
20. Morjani, H., & Madoulet, C. Immunosuppressors as multidrug resistance reversal agents. Methods Mol. Biol. 596, 433-446 (2010
21. Bing, P., Maode, L., Li, F., & Sheng, H. Comparison of expression of TGF-beta 1, its receptors TGF-beta 1R-I and TGF-beta 1R-II in rat kidneys during chronic nephropathy induced by cyclosporine and tacrolimus. Transplant Proc. 38, 2180-2182 (2006
22. Chi, J., et al. Cyclosporin A induces apoptosis in H9c2 cardiomyoblast cells through calcium-sensing receptor-mediated activation of the ERK MAPK and p38 MAPK pathways. Mol. Cell Biochem. 367, 227-236 (2012
23. Erlanson, D. A. Introduction to fragment-based drug discovery. Top. Curr. Chem. 317, 1-32 (2012
24. Hajduk, P. J., & Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 6, 211-219 (2007
25. Wolkenstein, P., et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 5, 255-258 (1995
26. Woosley, R. L., et al. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N. Engl. J. Med. 298, 1157-1159 (1978
27. Coelmont, L., et al. Debio-025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob. Agents Chemother. 53, 967-976 (2009
28. Fruman, D. A., Klee, C. B., Bierer, B. E., & Burakoff, S. J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK-506 and cyclosporin A. Proc. Natl Acad. Sci. USA 89, 3686-3690 (1992
29. Murray, C. W., & Rees, D. C. The rise of fragment-based drug discovery. Nat. Chem. 1, 187-192 (2009
30. Baker, M. Fragment-based lead discovery grows up. Nat. Rev. Drug Discov. 12, 5-7 (2013
31. Eitner, K., & Koch, U. From fragment screening to potent binders: strategies for fragment-To-lead evolution. Mini Rev. Med. Chem. 9, 956-961 (2009
32. Howard, B. R., Vajdos, F. F., Li, S., Sundquist, W. I., & Hill, C. P. Structural insights into the catalytic mechanism of cyclophilin A. Nat. Struct. Biol. 10, 475-481 (2003
33. Sweeney, Z. K., Fu, J., & Wiedmann, B. From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds. J. Med. Chem. 57, 7145-7159 (2014
34. Chung, S., Parker, J. B., Bianchet, M., Amzel, L. M., & Stivers, J. T. Impact of linker strain and flexibility in the design of a fragment-based inhibitor. Nat. Chem. Biol. 5, 407-413 (2009
35. Guichou, J. F., et al. Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin. J. Med. Chem. 49, 900-910 (2006
36. Li, J., et al. Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid. Bioorg. Med. Chem. 17, 3177-3188 (2009
37. Ni, S., et al. Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach. J. Med. Chem. 52, 5295-5298 (2009
38. Daum, S., et al. Isoform-specific inhibition of cyclophilins. Biochemistry 48, 6268-6277 (2009
39. Dunsmore, C. J., et al. Design and synthesis of conformationally constrained cyclophilin inhibitors showing a cyclosporin-A phenotype in C. elegans. Chembiochem 12, 802-810 (2011
40. Yang, S., et al. Structure-based discovery of novel cyclophilin A inhibitors for the treatment of hepatitis C virus infections. J. Med. Chem. 58, 9546-9561 (2015
41. Jhoti, H., Williams, G., Rees, D. C., & Murray, C. W. The rule of three for fragment-based drug discovery: where are we now? Nat. Rev. Drug Discov. 12, 644-645 (2013
42. Douguet, D., Munier-Lehmann, H., Labesse, G., & Pochet, S. LEA3D: a computer-Aided ligand design for structure-based drug design. J. Med. Chem. 48, 2457-2468 (2005
43. Kramer, B., Rarey, M., & Lengauer, T. Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 37, 228-241 (1999
44. Schlatter, D., et al. Crystal engineering yields crystals of cyclophilin D diffracting to 1.7A resolution. Acta Crystallogr. D Biol. Crystallogr. 61, 513-519 (2005
45. Krieger, N., Lohmann, V., & Bartenschlager, R. Enhancement of hepatitis C virus RNA replication by cell culture-Adaptive mutations. J. Virol. 75, 4614-4624 (2001